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ABSTRACT	  
Purpose:	  Our	  aim	  was	  to	  assess	  the	  prognostic	  and	  predictive	  value	  of	  somatostatin	  receptor	  2	  
(sstr2)	  in	  neuroendocrine	  tumors	  (NET).	  
Methods:	   We	   established	   a	   tissue	  microarray	   and	   imaging	   database	   from	  NET	   patients	   that	  
received	   sstr2-­‐targeted	   radiopeptide	   therapy	   with	   yttrium-­‐90-­‐DOTATOC,	   lutetium-­‐177-­‐
DOTATOC	  or	   alternative	   treatment.	  We	  used	  univariate	   and	  multivariate	   analyses	   to	   identify	  
prognostic	   and	   predictive	   markers	   for	   overall	   survival,	   including	   sstr2-­‐imaging	   and	   sstr2-­‐
immunohistochemistry.	  	  
Results:	  We	  included	  a	  total	  of	  279	  patients.	  In	  these	  patients,	  sstr2-­‐immunohistochemistry	  was	  
an	  independent	  prognostic	  marker	  for	  overall	  survival	  (HR:	  0.82,	  95%CI:	  0.67	  -­‐	  0.99,	  n	  =	  279,	  p	  =	  
0.037).	  In	  DOTATOC	  patients,	  sstr2-­‐expression	  on	  immunohistochemistry	  correlated	  with	  tumor	  
uptake	  on	  sstr2-­‐imaging	  (n	  =	  170,	  p	  <	  0.001);	  however,	  sstr2-­‐imaging	  showed	  a	  higher	  prognostic	  
accuracy	  (positive	  predictive	  value:	  +27%,	  95%CI:	  3	  -­‐	  56%,	  p	  =	  0.025).	  Sstr2-­‐expression	  did	  not	  
predict	  a	  benefit	  of	  DOTATOC	  over	  alternative	  treatment	  (p	  =	  0.93).	  
Conclusions:	   Our	   results	   suggest	   sstr2	   as	   independent	   prognostic	   marker	   in	   NET.	   Sstr2-­‐
immunohistochemistry	  correlates	  with	   sstr2-­‐imaging;	  however,	   sstr2-­‐imaging	   is	  more	  accurate	  
for	  determining	  the	  individual	  prognosis.	  
	  
Key	  words:	  PRRT,	  targeted	  therapy,	  metabolic	  therapy,	  tailored	  therapy,	  individualized	  therapy	  	  
	  
	  
	   	  
3	  
INTRODUCTION	  
Prognostic	  markers	  offer	  insight	  into	  the	  biology	  and	  natural	  course	  of	  a	  disease.	  They	  provide	  
useful	  information	  about	  the	  aggressiveness	  of	  the	  disease	  and	  the	  risk	  of	  recurrence	  or	  death.	  
Predictive	  markers,	  on	  the	  other	  hand,	  indicate	  a	  benefit	  of	  a	  certain	  therapy	  over	  alternative	  
treatments,	   and	   allow	   physicians	   to	   tailor	   therapeutic	   interventions	   to	   achieve	   the	   most	  
favorable	  outcome.	  
Such	   favorable	   outcomes	   have	   been	   found	   after	   somatostatin	   receptor	   2	   (sstr2)-­‐targeted	  
radiopeptide	  therapy	  in	  patients	  with	  neuroendocrine	  tumors	  (NET)	  that	  express	  high	  levels	  of	  
sstr2	  [1].	  However,	  it	  is	  unclear	  whether	  these	  outcomes	  reflect	  treatment	  effects	  or	  favorable	  
prognosis.	   In	   other	   words,	   is	   high	   sstr2-­‐expression	   a	   predictive	   marker	   for	   successful	   sstr2-­‐
targeted	  therapy	  or	  a	  prognostic	  marker	  for	  a	  benign	  course	  of	  disease?	  
To	  answer	   this	  question,	  and	   to	  provide	  a	   framework	   for	   improved	  patient	  management	  and	  
meaningful	   interpretation	   of	   treatment	   effects	   in	   NET,	   we	   investigated	   the	   prognostic	   and	  
predictive	  value	  of	  sstr2-­‐imaging	  and	  sstr2-­‐immunohistochemistry.	  
	  





We	  included	  patients	  with	  histologically	  confirmed	  NET	  who	  had	  been	  enrolled	  in	  a	  prospective	  
trial	   investigating	   the	   benefit	   of	   treatment	   with	   radiolabeled	   DOTATOC	   (tetraazacyclo-­‐
dodecane-­‐tetraacetic	   acid	   modified	   somatostatin	   analog	   Tyr3-­‐octreotide).	   This	   study	   was	  
designed	   and	   carried	   out	   according	   to	   good	   clinical	   practice,	   Swiss	   drug	   laws,	   and	   the	  
Declaration	  of	  Helsinki.	   Its	  protocol	  was	  registered	   (ClinicalTrials.gov	   identifier:	  NCT00978211)	  
and	  approved	  by	  the	  Basel	  ethics	  committee	  for	  human	  studies	  (#120/1997).	  Written	  informed	  
consent	  was	  obtained	  from	  all	  participants	  or	  their	  legal	  representatives.	  Patients	  were	  enrolled	  
and	   treated	  with	   yttrium-­‐90-­‐DOTATOC	  and	   lutetium-­‐177-­‐DOTATOC	  at	   the	  University	  Hospital	  
Basel,	  Switzerland	  as	  previously	  described	  [2-­‐4].	  
To	  assess	  the	  prognostic	  value	  of	  sstr2	   in	  a	  broad	  patient	  spectrum,	  we	  also	   included	  patients	  
with	   histologically	   confirmed	   pancreatic	   NET	   who	   had	   not	   been	   enrolled	   and	   had	   been	  
systematically	  investigated	  at	  the	  University	  Hospital	  Bern,	  Switzerland	  as	  previously	  described	  
[5].	  Tumor	   samples	  were	   collected	  at	   the	   study	   center	  and	   the	  main	   referring	   centers.	   Tissue	  
collection	   and	   analyses	   were	   approved	   by	   the	   Basel	   ethics	   committee	   for	   human	   studies	  
(#17/2010)	  and	  the	  Bern	  ethics	  committee	  for	  human	  studies	  (#200/2014).	  	  
Follow-­‐up	  data	  were	  obtained	  from	  referring	  physicians,	  the	  patients’	  primary	  practitioners,	  or	  
directly	   from	   the	   patient.	   All	   follow-­‐up	   data	   were	   centrally	   collected	   and	   each	   case	   was	  
reviewed	   and	   approved	   for	   completeness	   at	   the	   study	   center.	   Data	   were	   collected	   until	   the	  
patient’s	  death,	  including	  survival	  and	  long-­‐term	  toxicities.	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Sstr2-­‐imaging	  
Sstr2-­‐imaging	  was	   performed	   in	  DOTATOC	  patients	   as	   previously	   described	   [6,	   7].	   Specifically,	  
intra-­‐therapeutic	  DOTATOC	  accumulation	  in	  the	  lesion	  with	  the	  highest	  uptake	  among	  all	  visible	  
tumor	   lesions	   was	   scored	   by	   three	   nuclear	   medicine	   physicians,	   blinded	   to	   the	   patient’s	  
baseline	  and	  follow-­‐up	  data,	  and	  based	  on	  the	  following	  four-­‐point	  scale:	  no	  uptake	  (score	  0),	  
or	   uptake	   lower	   (score	   1),	   equal	   to	   (score	   2),	   or	   higher	   than	   liver	   uptake	   (score	   3).	   Cases	   of	  
disagreement	  were	  re-­‐assessed	  and	  scored	  by	  consensus.	  
	  
Sstr2-­‐immunohistochemistry	  
Two	   to	   three	   NET	   tissue	   cores	   per	   patient	   were	   formalin-­‐fixed	   and	   paraffin-­‐embedded	   in	   a	  
tissue	  microarray	  format.	  Subsequently,	  sstr2-­‐staining	  was	  performed	  using	  the	  UMB-­‐1	  antibody	  
(Biotrend,	  Cologne,	  Germany)	  [8].	  
Sstr2-­‐expression	  was	  scored	  by	  two	  pathologists	  blinded	  to	  patient	  data	  using	  a	  four-­‐point	  scale:	  
absent	  staining	  (score	  0),	  faint	  staining	  at	  100x	  magnification	  (score	  1),	  strong	  staining	  at	  100x	  
magnification	  not	  involving	  the	  entire	  circumference	  at	  400x	  magnification	  (score	  2),	  and	  strong	  
staining	  at	  100x	  magnification	   involving	   the	  entire	  circumference	  at	  400x	  magnification	   (score	  
3).	  Only	  membranous	  sstr2-­‐staining	  was	  evaluated,	  and	  the	  highest	  score	  of	  the	  tissue	  cores	  for	  
each	  patient	  was	  used.	  Cases	  of	  disagreement	  were	  re-­‐assessed	  and	  scored	  by	  consensus.	  	  
Ki-­‐67-­‐staining	   was	   performed	   using	   the	   MIB1-­‐clone	   antibody	   (Dako,	   Carpentaria,	   CA)	   [8].	  





Our	  primary	  hypothesis	  was	  an	  independent	  prognostic	  value	  of	  sstr2	  in	  NET.	  The	  association	  of	  
sstr2-­‐immunohistochemistry	  (score	  0	  vs.	  1	  vs.	  2	  vs.	  3)	  and	  survival	  was	  examined	  by	  univariate	  
generalized	  Wilcoxon	  test	  and	  multivariate	  Cox	  regression.	  Cox	  regression	  was	  performed	  with	  
survival	  from	  time	  of	  diagnosis	  as	  dependent	  variable.	  Independent	  co-­‐variables	  were	  age	  (per	  
year),	   histology	   (carcinoid	   vs.	   pancreatic	  NET	   vs.	   rare	  NET),	   disease	  extent	   (metastases	   vs.	   no	  
metastases),	  and	  Ki-­‐67	  expression	  or	  tumor	  grade	  (G1	  vs.	  G2	  vs.	  G3).	  
Associations	  of	  sstr2-­‐immunohistochemistry	  with	  sstr2-­‐imaging	  and	  tumor	  grade	  were	  analyzed	  
using	  Pearson's	  X2	   test.	  The	  prognostic	  value	  of	  positive	  sstr2-­‐imaging	   (score	  >	  2)	  and	  positive	  
sstr2-­‐immunohistochemistry	  (score	  ≥	  2)	  were	  compared	  as	  described	  before	  [10].	  	  
Our	   secondary	   hypothesis	   was	   an	   independent	   predictive	   value	   of	   sstr2	   for	   a	   benefit	   of	  
DOTATOC	  over	  alternative	  treatment.	  The	  predictive	  value	  was	  tested	  using	  cox	  regression	  with	  
an	   interaction	   test	   for	   sstr2-­‐immunohistochemistry	  and	  DOTATOC	   treatment.	  As	  all	  DOTATOC	  
patients	  had	  metastasized	  disease	  and	  all	  controls	  had	  pancreatic	  NET,	  the	  predictive	  value	  of	  
sstr2	  was	  tested	  in	  metastasized	  pancreatic	  NET	  receiving	  DOTATOC	  or	  alternative	  treatment.	  
We	   had	   previously	   found	   a	   benefit	   of	   yttrium-­‐90-­‐DOTATOC	   plus	   lutetium-­‐177-­‐DOTATOC	   over	  
yttrium-­‐90-­‐DOTATOC	   alone,	  without	   adjusting	   for	   tumor	   grade	   and	   sstr2-­‐expression	   [3].	   Thus,	  
we	  repeated	  this	  analysis	  additionally	  adjusting	  for	  both	  factors,	  and	  assessed	  the	  frequency	  of	  
renal	  toxicity	  after	  DOTATOC	  taking	  into	  account	  the	  competing	  risk	  of	  death.	  
Effect	  estimates	  were	  expressed	  as	  hazard	  ratios	  (HRs)	  with	  95%	  confidence	  intervals	  (CIs).	  Two-­‐
sided	   p-­‐values	   of	   <	   0.05	   were	   considered	   statistically	   significant.	   Results	   were	   reported	  




Between	  October	   1997	   and	   February	   2010,	   170	   patients	  with	   available	   tumor	   samples	  were	  
enrolled	  for	  DOTATOC	  (Figure	  1).	  Treatment	  prior	  to	  DOTATOC	  included	  surgery	  in	  140	  patients	  
(82.4%),	  chemotherapy	  in	  27	  patients	  (15.9%),	  and	  radiation	  therapy	   in	  16	  patients	  (9.4%,).	   In	  
addition,	   109	   controls	  were	   included.	   All	   of	   them	   received	   surgery;	   those	  with	  metastasized	  
disease	   additionally	   received	   somatostatin	   analogs	   (33.9%),	   chemotherapy	   (21.1%),	   selective	  
arterial	   chemo-­‐embolization	   (0.9%),	   and	   radiation	   therapy	   (0.9%).	  Patients’	  characteristics	  are	  
shown	  in	  Table	  1.	  	  
The	  279	  NET	  comprised	  150	  (53.8%)	  pancreatic	  NET,	  84	  (30.1%)	  carcinoids,	  and	  45	  (16.1%)	  rare	  
NET.	  The	  84	  carcinoids	  comprised	  60	  (71.4%)	  from	  the	  small	  intestine,	  7	  (8.3%)	  from	  the	  large	  
intestine,	  1	  from	  the	  stomach	  (1.2%),	  9	  from	  the	  bronchus	  (10.7%),	  3	  (3.6%)	  from	  the	  thymus,	  
and	  4	  (4.8%)	  from	  an	  unknown	  primary.	  The	  45	  rare	  NET	  comprised	  9	  (20.0%)	  medullary	  thyroid	  
cancers,	  7	  (15.6%)	  Merkel	  Cell	  cancers,	  6	  (13.3%)	  paraganglioma,	  1	  (2.2%)	  pheochromocytoma,	  
1	   (2.2%)	   NET	   of	   the	   kidney,	   1	   (2.2%)	   NET	   of	   the	   prostate,	   and	   20	   (44.4%)	   NET	   of	   unknown	  
primary.	  
The	  279	   tumor	   tissues	  had	  a	  median	  Ki-­‐67-­‐expression	  of	  1.4	   (range:	  0	   -­‐	   95.8,	  Table	   1).	   Sstr2-­‐
immunohistochemistry	  was	  feasible	  in	  241	  cases	  (86.4%).	  Staining	  was	  homogenous	  through	  all	  
tissue	   cores	   in	   202	   cases	   (83.8%)	   and	  heterogeneous	   in	   39	   cases	   (16.2%).	   The	   assessment	  of	  
sstr2	  expression	  by	  two	  pathologists	  showed	  a	  high	  concordance.	  Scoring	  slightly	  diverged	  in	  8	  
of	  241	  cases	   (3.3%),	  with	  one	  point	  difference	   in	  scoring,	  and	  the	  final	  score	  was	  assigned	  by	  
consensus.	  Low	  tumor	  grades	  were	  correlated	  with	  high	  scores	  on	  sstr2-­‐immunohistochemistry	  
(n	  =	  279,	  p	  =	  0.012,	  Pearson's	  X2	  test).	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Sstr2-­‐immunohistochemistry	  as	  prognostic	  marker	  in	  NET	  
Patients	  with	  score	  3	   tumor	  sstr2-­‐immunohistochemistry	  had	  a	   longer	   survival	   from	  diagnosis	  
than	  patients	  with	  score	  2,	  1,	  or	  0	  (164.2	  vs.	  140.2	  vs.	  107.6	  vs.	  127.8	  months;	  HR:	  0.82,	  95%CI:	  
0.67	  -­‐	  0.99;	  n	  =	  240,	  p	  =	  0.037,	  multivariate	  cox	  regression,	  Figure	  2A,	  Table	  2).	  Similar	  results	  
were	  found	  when	  adjusting	  for	  the	  actual	  Ki-­‐67	  expression	  instead	  of	  the	  tumor	  grade,	  or	  when	  
using	  univariate	  analysis	  (n	  =	  240;	  p	  =	  0.024,	  generalized	  Wilcoxon	  test).	  	  
Additionally,	   carcinoid	   patients	   survived	   longer	   than	   patients	   with	   rare	   NET	   (184.9	   vs.	   82.6	  
months;	   HR:	   0.37,	   95%CI:	   0.21	   -­‐	   0.63;	   n	   =	   129;	  p	   <	   0.001,	   cox	   regression,	   Figure	   2B),	   as	   did	  
patients	  with	  pancreatic	  NET	  (164.0	  vs.	  82.6	  months;	  HR:	  0.40,	  95%CI:	  0.23	  -­‐	  0.69;	  n	  =	  195;	  p	  =	  
0.001,	  cox	  regression,	  Figure	  2B).	  Patients	  with	  G1	  tumors	  survived	  longer	  than	  patients	  with	  G2	  
or	  G3	  tumors	  (185.6	  vs.	  99.8	  vs.	  19.1	  months;	  HR:	  0.32,	  95%CI:	  0.23	  -­‐	  0.4;	  n	  =	  240;	  p	  <	  0.001,	  cox	  
regression,	  Figure	  2C).	  
	  
Sstr2-­‐imaging	  vs.	  sstr2-­‐immunohistochemistry	  
Tumor	  uptake	  on	  sstr2-­‐imaging	  correlated	  with	  sstr2-­‐expression	  on	  immunohistochemistry	  (n	  =	  
170,	  p	  <	  0.001,	  Pearson's	  X2	  test,	  Figure	  3A).	  
Sstr2-­‐imaging	   had	   higher	   accuracy	   than	   sstr2-­‐immunohistochemistry	   as	   prognostic	  marker	   for	  
survival	  after	  DOTATOC	  (PPV	  (t):	  27%	  higher,	  95%CI:	  3	  -­‐	  56%;	  n	  =	  170,	  p	  =	  0.025;	  NPV	  (t):	  32%	  
higher,	  95%CI:	   -­‐21	   -­‐	  121%;	  n	  =	  170,	  p	  =	  0.28).	  The	  positive	  and	  negative	  prognostic	  values	  of	  
sstr2-­‐imaging	  were	  higher	  alone,	  compared	  with	  combining	  the	  results	  from	  sstr2-­‐imaging	  and	  
sstr2-­‐immunohistochemistry	  (Figure	  3B).	  
	   	  
9	  
Sstr2	  as	  predictive	  marker	  for	  sstr2-­‐targeted	  radiopeptide	  therapy	  
A	  total	  of	  61	  patients	  with	  metastatic	  pancreatic	  NET	  were	  treated	  with	  DOTATOC	  (n	  =	  41)	  or	  
alternative	  treatment	  (n	  =	  20),	  and	  had	  a	  median	  survival	  of	  129.9	  months	  from	  diagnosis.	  
There	   was	   a	   non-­‐significant	   trend	   towards	   longer	   survival	   after	   DOTATOC	   vs.	   alternative	  
treatment	  (142.5	  vs.	  95.5	  months;	  HR:	  0.70,	  95%CI:	  0.29	  -­‐	  1.71;	  n	  =	  61,	  p	  =	  0.43,	  cox	  regression,	  
Figure	   4A).	   In	   tumors	   with	   sstr2-­‐expression	   (scores	   1,	   2	   and	   3),	   this	   trend	   was	   pronounced	  
(139.2	  vs.	  73.9	  months;	  HR:	  0.61,	  95%CI:	  0.22	  -­‐	  1.67;	  n	  =	  50,	  p	  =	  0.33,	  cox	  regression,	  Figure	  4B).	  
Conversely,	  in	  tumors	  without	  sstr2-­‐expression	  (score	  0),	  no	  difference	  between	  survivals	  in	  the	  
two	  groups	  was	  observed	   (103.3	  vs.	   113.7;	  HR:	  1.01,	  95%CI:	  0.10	   -­‐	  10.5,	  n	  =	  11,	  p	   =	  1.0,	   cox	  
regression,	  Figure	  4C).	  
The	   interaction	   test	  did	  not	   indicate	  a	  predictive	  value	  of	   sstr2;	   the	  benefit	  of	  DOTATOC	  over	  
alternative	  treatment	  was	  not	  significantly	  different	  in	  sstr2-­‐positive	  vs.	  sstr2-­‐negative	  cases	  (p	  =	  
0.93).	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DISCUSSION	  
Our	   results	   suggest	   sstr2-­‐immunohistochemistry	   as	   a	   prognostic	   marker	   in	   NET	   that	   is	  
independent	   from	   tumor	   histology,	   grade,	   stage,	   and	   patient	   age.	   While	   sstr2-­‐
immunohistochemistry	   correlates	   with	   sstr2-­‐imaging,	   sstr2-­‐imaging	   has	   a	   higher	   prognostic	  
accuracy.	  The	  superior	  prognostic	  accuracy	  might	  be	  due	  to	  the	  fact	  that	  sstr2-­‐imaging	  provides	  
a	  whole-­‐body	  read-­‐out,	  while	  sstr2-­‐immunohistochemistry	  can	  be	  associated	  with	  a	  significant	  
sampling	   error.	   The	   results	   did	   not	   confirm	   sstr2-­‐expression	   as	   predictive	   marker	   for	   sstr2-­‐
targeted	  radiopeptide	  therapy,	  and	  suggest	  a	  trend	  towards	  longer	  survival	  with	  sstr2-­‐targeted	  
radiopeptide	  therapy	  in	  sstr2-­‐positive	  cases.	  	  
	  
Strengths	  and	  limitations	  
Strengths	  of	   the	  present	  study	   include	  the	  combination	  of	  tissue	  markers,	  molecular	   imaging,	  
and	   long-­‐term	   follow-­‐up	   in	   a	   wide	   spectrum	   of	   NET	   patients.	   The	   tissue	   microarray	   format	  
facilitated	  standardized	  marker	  analyses,	  the	  large	  number	  of	  patients	  and	  the	  completeness	  of	  
follow-­‐up	   facilitated	  comprehensive	  survival	  analyses,	  and	  the	  spectrum	  of	   tumor	  histologies,	  
grades,	   and	   stages	  ensures	   general	   applicability	  of	   the	  present	   results.	  However,	   the	  present	  
study	  was	  not	  a	  randomized	  trial,	  and	  has	  the	  known	  limitations	  of	  a	  non-­‐randomized	  study.	  To	  
assess	  the	  prognostic	  value	  of	  sstr2	  in	  a	  spectrum	  of	  NET	  patients,	  we	  included	  those	  that	  did	  or	  
did	  not	  qualify	  for	  DOTATOC	  treatment.	  To	  assess	  the	  predictive	  value	  of	  sstr2,	  we	  subsequently	  
matched	   patients	   from	   these	   groups	   by	   tumor	   type	   (pancreatic	   NET)	   and	   tumor	   extent	  
(metastasized	  disease).	  However,	  the	  analysis	  on	  the	  predictive	  value	  of	  sstr2	  was	  limited	  by	  the	  
low	  number	  of	  patients	  with	  metastasized	  pancreatic	  NET,	  and	  the	  comparison	  of	  imaging	  and	  
immunohistochemistry	  was	  limited	  to	  DOTATOC	  patients.	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Comparison	  to	  other	  studies	  
The	   increasing	   availability	   of	   targeted	   therapies	   is	   generating	   an	   increasing	   demand	   for	  
modalities	  that	  reliably	  assess	  target	  expression,	  its	  predictive	  value,	  and	  individual	  prognosis.	  
Among	   such	  modalities,	   immunohistochemistry	   allows	   detailed	   assessment	   of	   specific	   tissue	  
samples,	   while	   imaging	   allows	   a	   less	   detailed	   overview	   over	   the	   entire	   body.	   Studies	   that	  
compare	   the	   accuracy	   of	   both	   modalities	   for	   clinically	   relevant	   molecular	   targets	   will	   be	  
increasingly	  warranted	  in	  the	  future.	  	  
To	   the	   best	   of	   our	   knowledge,	   this	   is	   the	   first	   study	   to	   assess	   the	   prognostic	   value	   of	   sstr2-­‐
immunohistochemistry	  in	  a	  general	  NET	  cohort	  adjusted	  to	  tumor	  grade	  and	  type.	  Our	  results	  
concur	  with	  other	  studies,	  in	  which	  sstr2-­‐immunohistochemistry	  was	  found	  to	  be	  prognostic	  in	  
patients	  with	  carcinoids	  [12]	  and	  sstr2-­‐imaging	  was	  shown	  to	  be	  prognostic	  in	  NET	  patients	  [13],	  
although	  analyses	  were	  not	   adjusted	   to	   important	  prognostic	   factors	   like	   tumor	  grade	   in	   the	  
latter	   study.	   Furthermore,	   the	   present	   study	   is	   the	   first	   to	   compare	   the	   prognostic	   value	   of	  
sstr2-­‐imaging	  vs.	  sstr2-­‐immunohistochemistry.	  Its	  results	  support	  the	  current	  clinical	  practice	  of	  
favoring	  sstr2-­‐imaging.	  	  
Our	  results	  also	  show	  a	  trend	  towards	  longer	  overall	  survival	  after	  sstr2-­‐targeted	  radiopeptide	  
therapy	   over	   alternative	   treatment,	  which	   is	   in	   line	  with	   the	   overall	   survival	   benefit	   of	   sstr2-­‐
targeted	  radiopeptide	  therapy	  over	  somatostatin	  analogue	  treatment	  found	  in	  the	  preliminary	  
analysis	  of	  the	  ongoing	  NETTER-­‐1	  trial	  [14].	  
Finally,	   previous	   studies	   in	   NET	   with	   unknown	   sstr2-­‐expression	   and	   tumor	   grade	   indicated	  
superiority	   of	   sstr2-­‐targeted	   radiopeptide	   therapy	   with	   combined	   radioisotopes	   over	   single	  
radioisotopes	   [3,	   15].	   This	   superiority	  might	   be	   due	   to	   lutetium-­‐177	   being	  more	   effective	   in	  
irradiating	  small	   tumor	   lesions	  and	  yttrium-­‐90	  being	  more	  effective	   in	   irradiating	   large	   tumor	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Our	  results	  have	  implications	  for	  patient	  management	  and	  further	  research.	  Prognostic	  markers	  
have	  particular	  value	  for	  tumors	  with	  a	  wide	  spectrum	  of	  courses,	  such	  as	  NET	  [11].	  Based	  on	  
our	  results,	  sstr2	  can	  serve	  as	  prognostic	  marker	  and	  decision	  aid	  in	  determining	  whether	  a	  NET	  
patient	  should	  receive	  treatment	  and	  how	  aggressive	  the	  treatment	  should	  be.	  
Furthermore,	  immunohistochemistry	  and	  imaging	  can	  be	  used	  to	  assess	  tumor	  sstr2-­‐expression.	  
However,	   our	   results	   suggest	   that,	   in	   cases	   of	   discrepancies,	   imaging	   is	   more	   accurate	   for	  
determining	  the	  patient’s	  individual	  prognosis.	  	  
Finally,	  studies	  that	  stratify	  patients	  according	  to	  sstr2-­‐expression,	  e.g.	  surgical	  resection	  of	  NET	  
visible	  in	  sstr2-­‐imaging,	  are	  prone	  to	  bias	  favoring	  interventions	  in	  sstr2-­‐positive	  cases,	  and	  need	  
to	  be	  interpreted	  cautiously.	  Moreover,	  upcoming	  studies	  to	  evaluate	  prognostic	  factors	  in	  NET	  
should	  take	  sstr2-­‐expression	  into	  account	  for	  all	  analyses.	  	  
	  
Conclusions	  
Our	  results	  suggest	  sstr2	  as	  independent	  prognostic	  marker	  in	  NET.	  Sstr2-­‐immunohistochemistry	  
correlates	   with	   sstr2-­‐imaging;	   however,	   sstr2-­‐imaging	   is	   more	   accurate	   for	   determining	   the	  
individual	  prognosis.	  Studies	  exploring	  prognostic	  factors	  in	  NET	  should	  include	  sstr2-­‐expression	  
in	  all	  analyses.	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(n	  =	  279)	  
DOTATOC	  patients	  
(n	  =	  170)	  
Controls	  
(n	  =	  109)	  
	   	   	   	   	  
Gender	   females	   118	  (42.3%)	   68	  (40.0%)	   50	  (45.9%)	  
	   males	   161	  (57.7%)	   102	  (60.0%)	   59	  (54.1%)	  
Age	  (y)	   median	   59.6	   59.5	   59.7	  
	   range	   16.9	  -­‐	  95.1	   16.9	  -­‐	  81.4	   26.4	  -­‐	  95.1	  
Histology	   pancreatic	  NET	   150	  (53.8%)	   41	  (24.1%)	   109	  (100%)	  
	   carcinoid	   84	  (30.1%)	   84	  (49.4%)	   0	  (0%)	  
	   rare	  NET	   45	  (16.1%)	   45	  (26.5%)	   0	  (0%)	  
Extent	   no	  metastases	   57	  (20.4%)	   0	  (0%)	   57	  (52.3%)	  
	   metastases	   222	  (79.6%)	   170	  (100%)	   52	  (47.7%)	  
Grade	   G1	   175	  (62.7%)	   109	  (64.1%)	   66	  (60.6%)	  
	   G2	   74	  (26.5%)	   43	  (25.3%)	   31	  (28.4%)	  
	   G3	   26	  (9.3%)	   15	  (8.8%)	   11	  (10.1%)	  
	   unknown	   4	  (1.4%)	   3	  (1.8%)	   1	  (0.9%)	  
Ki67	  expression	   median	   1.4%	   1.2%	   1.8%	  
	   range	   0	  -­‐	  95.8%	   0%	  -­‐	  85.0%	   0%	  -­‐	  95.8%	  
Sstr2	  expression	   score	  0	   72	  (25.8%)	   45	  (26.5%)	   27	  (24.8%)	  
	   score	  1	   49	  (17.6%)	   38	  (22.4%)	   11	  (10.1%)	  
	   score	  2	   57	  (20.4%)	   39	  (22.9%)	   18	  (16.5%)	  
	   score	  3	   63	  (22.6%)	   47	  (27.6%)	   16	  (14.7%)	  
	   unknown	   38	  (13.6%)	   1	  (0.8%)	   37	  (33.9%)	  
	   	   	   	   	  




Table	  2.	  Prognostic	  Factors	  in	  NET	  
	  
Survival	  from	  diagnosis	  (n	  =	  279)	   Hazard	  ratio	  (95%CI)	  *	   	  	  	  p	  
Carcinoid	   (vs.	  rare	  NET)	   	   0.37	  (0.21	  -­‐	  0.63)	  <	  0.001	  
Pancreatic	  NET	   (vs.	  rare	  NET)	   	   	  0.40	  (0.23	  -­‐	  0.69)	   0.001	  
Sstr2	  expression	   (per	  score)	   	   0.82	  (0.67	  -­‐	  0.99)	   0.037	  
Age	   (per	  year)	   	   1.03	  (1.01	  -­‐	  1.05)	   0.005	  
Metastases	   (vs.	  no	  metastases)	   	   1.90	  (0.93	  -­‐	  3.88)	   0.078	  
Tumor	  grade	   (per	  grade)	   	   3.15	  (2.24	  -­‐	  4.44)	  <	  0.001	  
	   	   	   	  
Survival	  from	  DOTATOC	  (n	  =	  170)	   Hazard	  ratio	  (95%CI)	  *	   	  	  	  p	  
Y-­‐	  plus	  Lu-­‐DOTATOC	   (vs.	  Y-­‐DOTATOC)	   	   0.43	  (0.25	  -­‐	  0.74)	   0.02	  
Y-­‐	  plus	  Lu-­‐DOTATOC	   (vs.	  Lu-­‐DOTATOC)	   	   0.71	  (0.28	  -­‐	  1.85)	   0.48	  
Sstr2	  expression	   (per	  score)	   	   0.80	  (0.65	  -­‐	  0.98)	   0.031	  
Age	  	   (per	  year)	   	   	  1.01	  (0.99	  -­‐	  1.02)	   0.42	  
Tumor	  grade	   (per	  grade)	   	   2.70	  (1.91	  -­‐	  3.82)	  <	  0.001	  
	  
	   0.1	   1.0	   10	  
	   longer	  survival	   shorter	  survival	  
	   	   	  
*Estimates	  for	  each	  variable	  have	  been	  adjusted	  for	  all	  other	  variables	  listed.	  Similar	  results	  are	  found	  for	  
all	  variables	  listed	  when	  adjusting	  for	  Ki-­‐67	  expression	  instead	  of	  the	  tumor	  grade.	  
	  





Figure	  1.	  Patient	  flow.	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Figure	   2.	   Sstr2-­‐immunohistochemistry	   as	   prognostic	   marker	   in	   NET.	   Cox	   regression	   plots	  
demonstrating	   the	   survival	   of	   NET	   patients	   by	   tumor	   sstr2-­‐immunohistochemistry	   (A),	   tumor	  
type	  (B)	  and	  tumor	  grade	  (C).	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Figure	   3.	   Sstr2-­‐imaging	   vs.	   sstr2-­‐immunohistochemistry.	   Distribution	   of	   sstr2-­‐immuno-­‐
histochemistry	   results	   (score	   0,	   1,	   2,	   and	   3)	   and	   sstr2-­‐imaging	   results	   (score	   1,	   2,	   and	   3;	  A).	  
Positive	   and	   negative	   prognostic	   values	   for	   survival	   after	   DOTATOC	   of	   positive	   sstr2-­‐
immunohistochemistry	   (score	   ≥	   2),	   positive	   sstr2-­‐imaging	   (score	   >	   2)	   and	   their	   combination	  
(B,	  IHC	  =	  immunohistochemistry).	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Figure	   4.	   Sstr2	   as	   predictive	  marker	   for	   sstr2-­‐targeted	   radiopeptide	   therapy.	  Cox	   regression	  
plots	  demonstrating	  the	  survival	  of	  DOTATOC	  patients	  and	  controls,	  for	  all	  patients	  (A),	  patients	  
with	   positive	   sstr2-­‐immunohistochemistry	   (B),	   and	   patients	   with	   negative	   sstr2-­‐
immunohistochemistry	  (C).	  
	  
	  
